scholarly journals Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database

Cancer ◽  
2015 ◽  
Vol 122 (2) ◽  
pp. 222-229 ◽  
Author(s):  
Brian T. Hanyok ◽  
Lauren E. Howard ◽  
Christopher L. Amling ◽  
William J. Aronson ◽  
Matthew R. Cooperberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Hospital Database ◽  
Castration Resistant ◽  
Cancer Hospital

scholarly journals Predictors of skeletal‐related events and mortality in men with metastatic, castration‐resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

Cancer ◽  
2019 ◽  
Vol 125 (22) ◽  
pp. 4003-4010 ◽  
Author(s):  
Ingrid Lorese Tablazon ◽  
Lauren E. Howard ◽  
Amanda M. De Hoedt ◽  
William J. Aronson ◽  
Christopher J. Kane ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Equal Access ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Cancer Hospital ◽  
Skeletal Related Events

scholarly journals Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1864
Author(s):  
Jongsoo Lee ◽  
Jee Soo Park ◽  
Ji Eun Heo ◽  
Hyun Kyu Ahn ◽  
Won Sik Jang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Computed Tomography ◽  
Skeletal Muscle ◽  
Body Composition ◽  
Survival Rates ◽  
Castration Resistant Prostate Cancer ◽  
Vertebral Level ◽  
Skeletal Muscle Index ◽  
Castration Resistant ◽  
Muscle Attenuation

Limited studies have investigated the correlation between body composition and prostate cancer outcomes. We analyzed the effect of muscle mass and quality on castration-resistant prostate cancer (CRPC) outcomes. Skeletal muscle index (SMI) and skeletal muscle attenuation (SMA) were measured for 411 patients at the L3 vertebral level using computed tomography at CRPC diagnosis and were dived to low and high groups at the value of median. Analysis of the skeletal phenotypes and age (<70 and >70 years) was performed to evaluate the effect of SMI and SMA. The median survival rates for patients with low and high SMI were 19 and 24 months (p = 0.015), and those with low and high SMAs were 15 and 26 months (p < 0.001), respectively. In the subgroup analysis by age, SMA was a significant prognosticator in both groups, while SMI was a significant prognosticator only in patients aged >70 years. Patients with low SMA + low SMI had the worst prognosis. Muscle characteristics seems to be a prognosticator in survival of CRPC patients and may be considered in treatment planning.

Sign in / Sign up

Export Citation Format

Share Document